TOPAZ-1: NCT03875235: Phase 3: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer
First Posted 2019-03-14 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 ASCO Gastrointestinal Cancers Symposium Click here for details Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcita
Dec 15, 2022